Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07608432 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
A Phase 3 study, sponsored by Dyne Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT07608432 is a Phase 3 study that is actively recruiting participants, run by Dyne Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT07608432, a Phase 3 study, is actively recruiting participants, sponsored by Dyne Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
Interventions
- DRUG Placebo
- DRUG Zeleciment Rostudirsen (DYNE-251)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2032-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07608432
The ClinicalTrials.gov registry entry for NCT07608432 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dyne Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07608432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07608432 about?
NCT07608432 is a clinical study titled "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)". The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
What is the current status of trial NCT07608432?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2032-10.
What interventions are being tested in trial NCT07608432?
The interventions under investigation include: Placebo (DRUG), Zeleciment Rostudirsen (DYNE-251) (DRUG).
Who is sponsoring clinical trial NCT07608432?
This trial is sponsored by Dyne Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.